^
    Agilent's Ki-67 IHC MIB-1 pharmDx (Dako Omnis) companion diagnostic assay for the Dako Omnis advanced staining platform has been designed and tested to aid in evaluating risk of recurrence in early breast cancer (EBC). This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio.
    Cancer:
    Breast Cancer
    Drug:
    Verzenio (abemaciclib)
    Method:
    Immunohistochemistry (IHC)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    10/12/21
    BC
    -
    abemaciclib
    FDA
    Confirmatory trial(s)
    monarchE
    ,
    NCT03155997
    |
    J Clin Oncol